Metformin within a week of COVID cuts long COVID and death risk by 53%, study finds
Metformin within a week of COVID cuts long COVID and death risk by 53%, study finds
Metformin within a week of COVID cuts long COVID and death risk by 53%, study finds
Key points
اہم نکات
मुख्य बातें
- A study in the Journal of Medical Virology found that COVID-19 patients given metformin, a common diabetes drug, within six days of infection were 53 percent less likely to develop long COVID or die within six months.
- Researchers at the University of Minnesota Medical School compared 248 patients who received metformin with the same number given other drugs, using health records from more than 21 million people.
- Long COVID or death occurred in 4.0 percent of the metformin group, against 8.5 percent in the comparison group.
- A study in the Journal of Medical Virology found that COVID-19 patients given metformin, a common diabetes drug, within six days of infection were 53 percent less likely to develop long COVID or die within six months.
- Researchers at the University of Minnesota Medical School compared 248 patients who received metformin with the same number given other drugs, using health records from more than 21 million people.
- Long COVID or death occurred in 4.0 percent of the metformin group, against 8.5 percent in the comparison group.
- A study in the Journal of Medical Virology found that COVID-19 patients given metformin, a common diabetes drug, within six days of infection were 53 percent less likely to develop long COVID or die within six months.
- Researchers at the University of Minnesota Medical School compared 248 patients who received metformin with the same number given other drugs, using health records from more than 21 million people.
- Long COVID or death occurred in 4.0 percent of the metformin group, against 8.5 percent in the comparison group.
A study in the Journal of Medical Virology found that COVID-19 patients given metformin, a common diabetes drug, within six days of infection were 53 percent less likely to develop long COVID or die within six months. Researchers at the University of Minnesota Medical School compared 248 patients who received metformin with the same number given other drugs, using health records from more than 21 million people. Long COVID or death occurred in 4.0 percent of the metformin group, against 8.5 percent in the comparison group. The authors say the findings need to be confirmed in clinical trials before they can guide treatment.
A study in the Journal of Medical Virology found that COVID-19 patients given metformin, a common diabetes drug, within six days of infection were 53 percent less likely to develop long COVID or die within six months. Researchers at the University of Minnesota Medical School compared 248 patients who received metformin with the same number given other drugs, using health records from more than 21 million people. Long COVID or death occurred in 4.0 percent of the metformin group, against 8.5 percent in the comparison group. The authors say the findings need to be confirmed in clinical trials before they can guide treatment.
A study in the Journal of Medical Virology found that COVID-19 patients given metformin, a common diabetes drug, within six days of infection were 53 percent less likely to develop long COVID or die within six months. Researchers at the University of Minnesota Medical School compared 248 patients who received metformin with the same number given other drugs, using health records from more than 21 million people. Long COVID or death occurred in 4.0 percent of the metformin group, against 8.5 percent in the comparison group. The authors say the findings need to be confirmed in clinical trials before they can guide treatment.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।